Alpelisib drug instructions include dosage and contraindications

Alpelisib (Alpelisib) is a selective PI3Kα inhibitor commonly used to treat certain types of breast cancer, especially HR-positive, HER2-negative advanced or metastatic breast cancer carrying PIK3CA mutations. This article will introduce in detail the dosage, usage, contraindications, adverse reactions and precautions of Apelix from the perspective of drug instructions, to help patients and their families understand the clinical use information of this drug more comprehensively.

1. Basic information about drugs

The English name of AlpelisibAlpelisib and the trade name are Piqray, developed by Novartis. It is an oral small molecule targeted drug that mainly blocks the growth and spread of tumor cells by inhibiting the α isoform in the PI3K signaling pathway. This drug is often used in combination with fulvestrant (Fulvestrant) to treat PIK3CA mutation-positive HR+/HER2- advanced breast cancer patients who have previously received endocrine therapy.

2. Recommended dosage and usage

The common recommended dose of Apelvis is 300mg (i.e. 150mgtablets2tablets) once a day. It is recommended to take it after a meal to improve the absorption rate of the drug. If the patient experiences serious adverse reactions during use, such as hyperglycemia, rash or diarrhea, the dose can be reduced to 250mg or 200mg once a day according to the severity of the symptoms. If necessary, the medication can even be suspended and resumed after the symptoms are relieved.

It should be noted that patients should try to take the medicine at the same time every day during the medication period. If a dose is accidentally missed, the dose should be taken as soon as possible. If the retake time is close to the next dose time, the missed dose should be skipped to avoid double medication.

3. Taboos

According to the instructions for Apelvis, the following types of patients should avoid using the drug, or strictly assess the risks of taking the drug under the guidance of a doctor:

People who are allergic to Apelix or any of its excipients: If difficulty breathing, skin itching, urticaria, severe erythema or other allergic reactions occur, they should stop taking the drug immediately and seek medical advice.

Type Ⅰ diabetes or poorly controlled diabetes: Apelvis may significantly increase blood sugar levels. Diabetic patients are at higher risk and must be used with caution under strict monitoring and intervention.

Patients with severe hepatic insufficiency: Since Apelvis is mainly metabolized by the liver, abnormal liver function may affect drug metabolism and clearance, increasing the risk of adverse reactions.

Pregnant and lactating women: Apelvis may have potential effects on the fetus or infant. It is recommended to conduct a pregnancy test before taking the drug. Reliable contraceptive measures must be taken during the medication. Lactating women should stop breastfeeding.

4. Common adverse reactions

The instructions for Apelvis list a large number of adverse reactions, and patients need to closely observe the following categories during use:

Hyperglycemia: It is one of the most common adverse reactions. Especially in the early stages of use, patients should regularly detect fasting blood glucose and HbA1c indicators. Some patients may need to take oral hypoglycemic drugs or insulin.

Skin rash and allergic skin reactions: including erythema, itching, blisters, etc. In severe cases, erythema multiforme or Stevens-Johnson syndrome may develop.

Diarrhea and nausea: These are common discomforts of the digestive system. Symptoms can be relieved through dietary adjustments, fluid rehydration, and necessary medications.

Stomatitis and loss of appetite: Especially obvious after long-term use, it may affect nutritional status. It is recommended to cooperate with nutritional intervention.

Weight loss and fatigue: may be related to drug metabolism, and regular assessment of weight and physical status is also required.

5. Monitoring recommendations during medication

The instructions recommend that patients undergo the following monitoring regularly during treatment with Apelvis:

Blood sugar monitoring: It is recommended to test blood sugar at least once a week within the first two weeks after initial use, and monthly after stabilization.

Liver and renal function tests: Liver enzymes (ALT/AST) and renal function (creatinine, urea nitrogen) should be closely monitored, especially during combined therapy.

Skin observation: Take timely intervention when early signs of rash are detected.

Periodic imaging evaluation: to assess tumor response and treatment effectiveness.

6. Drug interactions

Apelix is mainly metabolized by CYP3A4 and UGT1A9, and the following drugs may interact with it:

CYP3A4Strong inhibitors (such as clarithromycin, ketoconazole) may increase the plasma concentration of apelvis and increase the risk of toxicity;

CYP3A4Inducers (such as rifampin, carbamazepine) may reduce drug efficacy;

When used in combination with other antidiabetic drugs (such as metformin, insulin), the dose of the antidiabetic drug should be adjusted.

Patients should inform their doctors of all medications they are taking during medication so that the treatment plan can be adjusted appropriately.

As a precisely targeted drug, Apelvis has shown good clinical effects in the treatment of specific breast cancer populations. But at the same time, its adverse reaction management and personalized medication strategies are particularly critical. During use, patients should strictly follow the doctor's recommendations when using the drug, pay attention to monitoring blood sugar and liver and kidney function, and promptly report any symptoms of physical discomfort. For breast cancer patients with PIK3CA mutation background, Apelvis provides a new treatment option, but drug safety still requires high attention, and full management must be carried out under the guidance of professional doctors.

Reference materials:https://www.drugs.com/